equinox glp-1 The gym is becoming a longevity hub. @equinox is evolving beyond fitness, with CEO Harvey Spevak telling Vogue, “people will pay anything for longevity.” As fitness and pharma converge, new models are The GLP-1 Advantage Beyond the

Canagliflozin is licensed to slow progression of DKD and dapagliflozin is licensed to slow progression of DKD and CKD in people with and without type 2 diabetes

Strong initial sales of the Wegovy pill will set the tone for the success of the drug in 2026 and beyond, especially in light of an anticipated orforglipron approval in April

Visceral fat and IGF-1 are meaningful measures, but they are surrogate/intermediate endpoints, not hard clinical outcomes like cardiovascular events

Cheng B

Thc phm b sung im bt cp ca vic b sung cht in gii qua cc loi thc phm t nhin chnh l khng bit hm lng chnh xc cc cht in gii l bao nhiu v thi gian ch bin n ung mt rt nhiu thi gian nn vic b sung cht in gii t ngun thc phm b sung ang l mt la chn hng u, nhanh chng v tin li

Burls 18